Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients

Cancer

Volumn 119, Issue 13, 2013, Pages 2438-2446

  Sellner, Leopold ^a   Heiss, Christiane ^b   Benner, Axel ^b   Raab, Marc S ^a   Hillengass, Jens ^a   Hose, Dirk ^a   Lehners, Nicola ^a   Egerer, Gerlinde ^a   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a   Neben, Kai ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

autologous stem cell transplantation; bortezomib; lenalidomide; multiple myeloma; salvage therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETRANSPLANTATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84879111740     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28104     Document Type: Article

References (25)

1. Harousseau JL, Moreau P,. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009; 360: 2645-2654.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
3. Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520.
5. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010; 28: 1209-1214.
6. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ,. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006; 91: 141-142.
7. Barlogie B, Anaissie E, van Rhee F, et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007; 20: 761-781.
8. Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma. 2009; 50: 1442-1447.
9. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009; 43: 417-422.
10. Blimark C, Veskovski L, Westin J, et al. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Eur J Haematol. 2011; 87: 117-122.
11. Cook G, Liakopoulou E, Pearce R, et al. British Society of Blood & Marrow Transplantation Clinical Trials Committee. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2011; 17: 1638-1645.
12. Fenk R, Liese V, Neubauer F, et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma. 2011; 52: 1455-1462.
13. Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012; 118: 3549-3555.
14. Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012; 18: 773-779.
15. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012; 119: 940-948.
16. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 1115-1123.
17. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
18. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23: 3412-3420.
19. Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012; 30: 1949-1952.
20. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1770-1781.
21. Morgan GJ, Gregory WM, Davies FE, et al. National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012; 119: 7-15.
22. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30: 2946-2955.
23. Ludwig H, Avet-Loiseau H, Blade J, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist. 2012; 17: 592-606.
24. Anderson KC, Alsina M, Bensinger W, et al. National Comprehensive Cancer Network. Multiple myeloma. J Natl Compr Canc Netw. 2011; 9: 1146-1183.
25. Reece DE,. Carfilzomib in multiple myeloma: gold, silver, or bronze? Blood. 2012; 120: 2776-2777.